The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company has $12.81 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $12.81 B | 38.87% |
2022-12-31 | $9.22 B | -6.11% |
2021-12-31 | $9.83 B | 15.93% |
2020-12-31 | $8.47 B | -78.76% |
2019-12-31 | $39.92 B | 395.27% |
2018-12-31 | $8.06 B | -17.65% |
2017-12-31 | $9.78 B | 52.41% |
2016-12-31 | $6.42 B | -23.6% |
2015-12-31 | $8.40 B | 0.39% |
2014-12-31 | $8.37 B | -15.37% |
2013-12-31 | $9.89 B | 24.06% |
2012-12-31 | $7.97 B | 1121.44% |
2011-12-31 | $0.65 B | 5960.32% |
2010-12-31 | $10.77 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $12.69 B | -0.98% | ๐บ๐ธ USA |
Eli Lilly LLY | $2.92 B | -77.16% | ๐บ๐ธ USA |
Amgen AMGN | $10.94 B | -14.61% | ๐บ๐ธ USA |
Biogen BIIB | $1.04 B | -91.81% | ๐บ๐ธ USA |
Gilead Sciences GILD | $7.26 B | -43.32% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $12.28 B | -4.18% | ๐บ๐ธ USA |
AstraZeneca AZN | $5.86 B | -54.28% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $6.35 B | -50.41% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $1.03 B | -91.95% | ๐บ๐ธ USA |